Dexamethasone Intravitreal Implant in Vitrectomized Versus Nonvitrectomized Eyes for Treatment of Patients with Persistent Diabetic Macular Edema

Abstract

In this study, the clinical findings were similar between nonvitrectomized and vitrectomized eyes. Intravitreal treatment with a DEX implant safely reduced DME and improved visual acuity in both groups. No statistically significant differences were found between the 2 groups regarding FT and BCVA.